Protein localization vector propagation: a method for improving the accuracy of drug repositioning

Yeu, Yunku; Yong-Jin, Yoon; Park, Sang‐Hyun

doi:10.1039/c5mb00306g

Cited by 55 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discovery and licensed use of a drug come with a long-gestation period. The cost of the new drug development process amounts to more than a billion dollars extending for a period of 10-15 years [4] with the success rate of only 2.01% [5]. This creates a lag in the productivity of pharmaceutical research to develop a new drug which results in a persistent gap between therapeutic needs and available treatments [6].…”

Section: Introductionmentioning

confidence: 99%

Drug repurposing approach to fight COVID-19

et al. 2020

View full text Add to dashboard Cite

Currently, there are no treatment options available for the deadly contagious disease, coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new uses for approved or investigational drugs and it is considered as a very effective strategy for drug discovery as it involves less time and cost to find a therapeutic agent in comparison to the de novo drug discovery process. The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective. Relevant articles with experimental studies conducted in-silico, in-vitro, in-vivo, clinical trials in humans, case reports, and news archives were selected for the review. Number of drugs such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, darunavir, arbidol, chloroquine, hydroxychloroquine, tocilizumab and interferons have shown inhibitory effects against the SARS-CoV2 invitro as well as in clinical conditions. These drugs either act through virus-related targets such as RNA genome, polypeptide packing and uptake pathways or target host-related pathways involving angiotensin-converting enzyme-2 (ACE2) receptors and inflammatory pathways. Using the basic knowledge of viral pathogenesis and pharmacodynamics of drugs as well as using computational tools, many drugs are currently in pipeline to be repurposed. In the current scenario, repositioning of the drugs could be considered the new avenue for the treatment of COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Drug repurposing approach to fight COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…According to a report by the Eastern Research Group (ERG) 1 , it usually takes 10-15 years to develop a new drug. However, the success rate of developing a new molecular entity is only 2.01% 2 , on average. As demonstrated in a report by the Food and Drug Administration (FDA), the number of drugs approved by the FDA has been declining since 1995 3 .…”

Section: Introductionmentioning

confidence: 99%

Review of Drug Repositioning Approaches and Resources

et al. 2018

View full text Add to dashboard Cite

Drug discovery is a time-consuming, high-investment, and high-risk process in traditional drug development. Drug repositioning has become a popular strategy in recent years. Different from traditional drug development strategies, the strategy is efficient, economical and riskless. There are usually three kinds of approaches: computational approaches, biological experimental approaches, and mixed approaches, all of which are widely used in drug repositioning. In this paper, we reviewed computational approaches and highlighted their characteristics to provide references for researchers to develop more powerful approaches. At the same time, the important findings obtained using these approaches are listed. Furthermore, we summarized 76 important resources about drug repositioning. Finally, challenges and opportunities in drug repositioning are discussed from multiple perspectives, including technology, commercial models, patents and investment.

show abstract

“…Computational drug repositioning approaches are usually based on similarities and shared properties. 2 Using abnormally expressed common gene sets is one of the valuable methods for presenting similarities:…”

Section: Methodsmentioning

confidence: 99%

“…Even after an enormous financial and time-consuming investment of typically 10-15 years, the approval rate of new drugs remained stagnant at 2.01%, on average, from 2000 to 2008. 1,2 As a result, drug repositioning using existing drugs for nontarget diseases has become an alternative methodology for deriving new drugs to market. [3][4][5][6] One method for this is a computational approach based on chemical-protein interactions, chemical-disease interactions, and omic interactions.…”

Section: Introductionmentioning

confidence: 99%

Pathway Interactions Based on Drug-Induced Datasets

Kim

2019

Cancer Inform

View full text Add to dashboard Cite

In this study, we identified enrichment pathway connections from MCF7 breast cancer epithelial cells that were treated with 87 drugs. We extracted drug-treated samples, where the sample size was greater than or equal to 5. The drugs included 17-allylaminogeldanamycin, LY294002, trichostatin A, valproic acid, sirolimus, and wortmannin, which had sample sizes of 11, 8, 7, 7, 7, and 5, respectively. We found meaningful pathways using gene set enrichment analysis and identified intradrug and interdrug pathway interactions, which implied the influence of drug combination. Among the top 20 enrichment pathways that were wortmannin induced, there were a total of 37 intradrug pathway interactions via common genes. Thirty-seven pathway interactions were induced by valproic acid, 11 induced by trichostatin A, 20 induced by LY294002, and 59 induced by sirolimus, all via common genes. The number of interdrug-induced pathway interactions ranged from one pair of pathways to 23. The pair of ERBB_SIGNALING and INSULIN_SIGNALING pathways showed the highest score from a pair of 2 individual drugs. The highest number of pathway interactions was observed between the drugs 17-allylamino-geldanamycin and LY294002.

show abstract

Protein localization vector propagation: a method for improving the accuracy of drug repositioning

Cited by 55 publications

References 29 publications

Drug repurposing approach to fight COVID-19

Drug repurposing approach to fight COVID-19

Review of Drug Repositioning Approaches and Resources

Pathway Interactions Based on Drug-Induced Datasets

Contact Info

Product

Resources

About